Thom Frielink

Thom is Associate at Curie Capital, involved with dealflow and portfolio management. Prior to his role at Curie Capital, he has gained 7 years of consultancy experience in raising funding for biopharmaceutical and medtech companies. In these functions Thom was involved in raising over €85 million non-dilutive capital and has developed in-depth knowledge on a wide range of topics in Life Sciences. In addition, he was the CEO of 2ndB, an Organ-on-Chip start-up. Thom has a BSc and MSc in Science and Innovation Management at Utrecht University, as well as an executive MBA from the Vlerick Business School.